Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in Pediatric Participants With Mild to Moderate Plaque Psoriasis
NCT06088199Phase 3Completed
- Sponsor
- Amgen
- Start
- Oct 2023
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of apremilast in plaque psoriasis, sponsored by Amgen. Primary endpoint: Number of Participants With Treatment-emergent Adverse Events. Started Oct 2023; status: completed.
02
Drugs
apremilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06088199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06088199.